Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique.

Siavoush Dastmalchi¹, Alireza Garjani², Nasrin Maleki², Golaleh Sheikhee³, Vida Baghchevan², Parisa Jafari-Azad², Hadi Valizadeh³, Mohammad Barzegar-Jalali³

¹Department of Medicinal Chemistry, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
²Department of Pharmacology, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
³Department of Pharmaceutics, School of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

Received 7 March 2005, Revised 14 March 2005, Accepted 23 March 2005, Published 02 August 2005

Abstract PURPOSE: Glibenclamide is practically insoluble in water and its GI absorption is limited by its dissolution rate. Therefore, to enhance the drug dissolution, serum concentrations and its hypoglycemic effects, it was formulated as solid dispersions and evaluated the relevant in vitro and in vivo parameters.

METHODS: The drug solid dispersions were prepared by solvent deposition technique using microcrystalline cellulose as the carrier in different ratios and their dissolution rates were compared to those of pure drug and its physical mixture with carrier. Drug serum concentrations and hypoglycemic effects in rabbits of pure drug and its corresponding solid dispersion were investigated. In order to elucidate the observed in vitro and in vivo differences, IR spectroscopy and x-ray diffraction patterns of the formulations were studied.

RESULTS: The solid dispersion with the drug to carrier ratio of 1:19 showed the highest dissolution rate with the dissolution efficiency (DE) of 44.42 in comparison to pure drug (DE = 3.82), physical mixture (DE = 4.91) and other solid dispersions (DE between 13.85-39.94) and also produced higher drug serum concentrations (more than 4 times at 6th hour post dose) as well as enhanced hypoglycemic effects relative to pure drug and its corresponding physical mixture.

CONCLUSIONS: Solvent deposition technique was proved an effective tool of increasing dissolution probably due to enhanced wettability and reduced drug particle size, which in turn led to enhancement drug serum concentrations and its hypoglycemic effects. Strong quantitative correlations were established between dissolution parameter and parameters related to serum concentrations as well as hypoglycemic effects.

INTRODUCTION

Glibenclamide is a second generation sulfonylurea used in the treatment of nonisulin dependent diabetes. Its hypoglycemic effect is mainly due to stimulation of insulin release from pancreatic beta cells and sensitization of the peripheral tissues to insulin (1).

Glibenclamide is practically insoluble in water (1) which leads to poor dissolution rate and subsequent decrease of its gastrointestinal (GI) absorption. Results of several investigations revealed that the absorption of glibenclamide was limited by its dissolution rate (2-9). The solid dispersion technique has been widely used to enhance dissolution rate of glibenclamide (3, 4, 7-9). In the present work, we have used solvent deposition (SD) technique to prepare glibenclamide solid dispersion in microcrystalline cellulose as the carrier at different ratios of drug to carrier. To the best of our knowledge, the solvent deposition technique and the carriers used in this work have not been applied to this drug. After performing the dissolution tests on pure drug (PD), physical mixture (PM) and SD formulations, x-ray diffraction pattern and infrared (IR) spectroscopic method have been employed to elucidate possible crystal changes in glibenclamide and drug-carrier interactions. Then the solid dispersion with the fastest dissolution rate was chosen for the further assessment of its serum concentrations as well as hypoglycemic effect in the rabbits.

MATERIALS AND METHODS

Glibenclamide (Chinoin Pharma, Hungaria), microcrystalline cellulose (Avicel PH-102 and RC591, FMC,
Brussels, Belgium), chloroform, potassium dihydrogen phosphate and disodium hydrogen phosphate (Merck, Darmstadt, Germany). Glucose assay kit (Darman Kave Res Lab, Isfahan, Iran).

**Preparation of SD systems and physical mixture**

Solvent deposition (SD) systems were prepared by dissolving glibenclamide in chloroform to produce a clear solution (10, 11), then the carrier was dispersed in the solution by stirring at 38±0.5°C and the solvent was removed by evaporation at 61±0.5°C while stirring. The resultant mass was dried at 40°C for 24 hours, pulverized and passed through a sieve with a mesh number of 120. Four different ratios of drug to carrier, namely 1:1, 1:5, 1:9 and 1:19 were used for SD formulations. A physical mixture containing one part drug and nineteen parts carrier was prepared using the bottle method.

The details of formulations are given in Table 1. From each batch four samples each equivalent to 20 mg of glibenclamide were taken and dissolved in methanol to reach appropriate dilution and then analyzed for the drug content by UV spectroscopy at 228 nm (UV-160 Shimadzo, Kyoto, Japan) using an appropriate Beer’s plot. The measured contents of glibenclamide in the physical mixture and the SD preparations were 20.05±0.1 mg.

**Table 1: Dissolution efficiency of different formulations.**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Code</th>
<th>DE&lt;sub&gt;100&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pure glibenclamide</td>
<td>PD</td>
<td>3.82</td>
</tr>
<tr>
<td>Physical mixture glibenclamide Avicel PH102 (1:19)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>PM</td>
<td>4.91</td>
</tr>
<tr>
<td>SD glibenclamide Avicel RC591 (1:1)</td>
<td>SD1</td>
<td>13.85</td>
</tr>
<tr>
<td>SD glibenclamide Avicel PH102 (1:1)</td>
<td>SD2</td>
<td>14.75</td>
</tr>
<tr>
<td>SD glibenclamide Avicel RC591 (1:5)</td>
<td>SD3</td>
<td>23.76</td>
</tr>
<tr>
<td>SD glibenclamide Avicel PH102 (1:5)</td>
<td>SD4</td>
<td>29.08</td>
</tr>
<tr>
<td>SD glibenclamide Avicel RC591(1:9)</td>
<td>SD5</td>
<td>37.30</td>
</tr>
<tr>
<td>SD glibenclamide Avicel PH102 (1:9)</td>
<td>SD6</td>
<td>39.94</td>
</tr>
<tr>
<td>SD glibenclamide Avicel PH102 (1:19)</td>
<td>SD7</td>
<td>44.42</td>
</tr>
<tr>
<td>SD glibenclamide Avicel RC591 (1:19)</td>
<td>SD8</td>
<td>45.29</td>
</tr>
</tbody>
</table>

<sup>a</sup>The figures inside the parentheses represent the ratio of drug to excipients.

**Dissolution rate studies**

The dissolution rate of glibenclamide in powder form, physical mixture and SD systems was studied using Levy’s beaker and stirrer method. Briefly, a sample equivalent to 20 mg of glibenclamide was added to 1000 ml of dissolution medium (phosphate buffer pH 7.25) and the mixture was stirred at 80 rpm with a two-bladed stirrer, 7.5 cm in diameter positioned 4 cm from the bottom of the beaker, at 37±0.3°C. Five millilitre samples of dissolution medium were withdrawn and filtered at different time intervals and assayed at 228 nm using a calibration curve. The drug concentration in each sample was corrected considering the concentrations in the previous samples. Each dissolution test was performed in triplicates.

**X-ray crystallography and IR spectroscopy**

X-ray diffraction patterns of the samples were obtained using an automatic powder diffractometer (Simens-850, Munich, Germany) using Cu Kα radiation at a scan rate of 2° min<sup>-1</sup> in terms of 2θ angle. The KBr disk sample preparation technique was used to obtain the IR spectra of the formulations on an IR spectrophotometer (FTIR 3400 Shimadzo, Kyoto, Japan).

**Glibenclamide serum concentration**

Ten white male healthy albino rabbits, 2.0±0.5 kg, were selected for this study. The permission for animal studies was obtained from the ethics committee of Tabriz University of Medical Sciences. Twelve hours before the experiment, the animals were fasted but had free access to tap water. Each of the animals received a single dose of glibenclamide (equivalent to 2 mg/kg) as pure drug, physical mixture of drug and Avicel PH102 (1:19) and its SD (1:19) in an aqueous suspension form according to a three-treatment randomized crossover schedule. Thus, each animal received three preparations on three treatment days with a two-week washout period between two successive dosing. The suspensions were prepared by dispersing the pure glibenclamide powder or its SD and PM preparations in 10 ml distilled water and administered in the esophagus with a syringe equipped with a number 12 catheter. Blood samples were collected predose (0 hr) and 1, 2, 3, 4, 5 and 6 hr post dose from marginal vein through a catheter inserted in the vein. Since, in the ascending part of the drug serum concentration curve, the absorption rate is dominant compared to elimination rate and the dissolution rate is the major factor affecting the serum concentrations, attempts were not made to collect the blood samples beyond six hours. After clot retraction, the samples centrifuged at 3500 rpm for 15 min, and then the serums were collected and kept at -20°C until analyzed.
An established HPLC method was used to measure the glibenclamide serum concentration (12). Briefly, the dried residue of the benzene extract obtained from 0.4 ml of acidified serum was redissolved in mobile phase (acetonitrile: 0.01 M phosphate buffer adjusted at pH 3.5 with the volume ratio of 40:60) and injected (20 μL) into the system (Cecil, UK). The mobile phase was delivered at the flow rate of 1 ml/min and separation was achieved on a C18 column (4.6×250 mm, 5 μ, Hichrom LTD, UK). Glibenclamide was detected at 225 nm wavelength with an ultraviolet detector. Chromatographic data was analyzed using Data Control program supplied with the HPLC system. A linear calibration plot prepared using peak height of the standard solutions (0.25-12 μg/ml) of glibenclamide was used to assay the concentration of the drug in the serum samples. The mean glibenclamide serum concentrations at different times for three different treatments were compared according to one-way ANOVA using the Student-Newman-Keuls method (13).

**Serum glucose concentration**

Twelve male rabbits, 2.5±0.6 kg, other than those used for glibenclamide serum concentration studies were subjected to the same circumstances and dosing schedule outlined above and their serum glucose concentrations were assayed based on the standard glucose oxidase method (14) using a commercial kit according to the supplied instruction. Briefly, to 20 μl of serum sample was added required reagents and enzyme and the mixture was vortexed and incubated at 37°C for 35 minutes. The intensity of the developed pink color was measured spectrometrically at 500 nm against a blank solution and the concentration of glucose was determined using a linear calibration plot. The same statistical analysis mentioned above was used to compare mean serum glucose concentrations at different time for various formulations.

**RESULTS**

**Dissolution rate**

The dissolution curves of pure glibenclamide, its physical mixture with the carrier Avicel PH102, and different SD systems containing the carriers Avicels PH102 and RC-591 are given in Figure 1.

A model-independent parameter, the dissolution efficiency (DE), was employed to compare the dissolution profiles of different formulations (15). $DE_T$ was calculated according to equation 1:

$$DE_T = \frac{\int_0^T y_t \cdot dt}{y_{100} \cdot T}$$

Where $y_t$ is percent of drug dissolved at any time $t$, $y_{100}$ denotes 100% dissolution, and the integral represents the area under dissolution curve between time zero and $T$. The time $T$ in this study was 120 minutes.

The calculated $DE_{120}$ values for different formulations in an ascending order are shown in Table 1.

**Drug serum concentrations**

The arithmetic mean serum concentrations of glibenclamide against time for pure drug, physical mixture of drug and Avicel PH102 (1:19) and its SD (1:19) are seen in Figure 2.
Figure 2: Glibenclamide mean serum concentrations vs. time in ten rabbits for (×) PD, (▲) PM, (●) SD7. The meanings of codes are given in Table 1. The vertical bars represent the standard error of mean. Glibenclamide serum concentrations for SD at times 2-6 hr were significantly higher than those for pure drug and the physical mixture (*P<0.001).

Serum glucose concentrations

The effects of pure glibenclamide and its PM and SD formulations on serum glucose concentrations at different time post-administration are seen in Figure 3.

Figure 3: Mean serum glucose concentrations vs. time in twelve rabbits for (×) PD, (▲) PM, (●) SD7. The meanings of codes are given in Table 1. The concentrations are the normalized serum glucose concentrations with respect to zero time concentration and expressed as percentages. The vertical bars represent the standard error of mean. Serum glucose concentrations for SD at times 1 and 2 hr were significantly lower than those for pure drug and the physical mixture (** P<0.01, *P<0.05).

DISCUSSION

It is evident from Figure 1 and the values of DE120 in Table 1 that the dissolution of glibenclamide is highly dependent on its formulations. The pure drug has the lowest and the SD preparations with drug to carrier ratio of 1:19 have the highest dissolution rates. The dissolution profiles of other formulations are between these two extremes. The higher dissolution rate of PM relative to pure drug is probably due to adsorption of the hydrophilic colloidal particles of microcrystalline cellulose onto the hydrophobic glibenclamide particles, which in turn might enhance the wettability of the latter particles (7,16). The drug dissolution is increased considerably from the SD formulations and this increase strongly depends on the ratio of drug to carrier regardless of the type of Avicel used. For example, the DE120 value is increased nearly three times by increasing the amount of carrier from one part to nineteen parts in the SD formulations. The possible causes for the enhanced dissolution from the SDs are increased wettability of the drug by the carrier, drug particle size reduction in the course of the solid dispersion preparation, polymorphic transformation of drug crystals and chemical interactions between drug and carrier (17).

Infrared spectroscopy and x-ray diffraction of glibenclamide powder and glibenclamide obtained after evaporation of its solution in chloroform show no changes in the drug molecule and crystal (Figure 4).

Figure 4: Infrared spectra (panel A) and x-ray diffractogram (panel B) of pure glibenclamide (top) and glibenclamide obtained after evaporation of its solution in chloroform (bottom). T is transmittance and ν is the wave number.
No changes in the IR and x-ray patterns of SD and PM formulations were observed (Figure 5).

These observations indicate that the enhanced dissolution for SD formulations is due to the increase of effective surface area of glibenclamide because of the reduction of its particle size as well as an increase of its wettability by the carriers.

PM and PD together with one of the SD formulations exhibiting the highest dissolution rate i.e., SD7 were subjected to further in vivo studies. As it is evident from the statistical analysis the glibenclamide, serum concentrations from SD7 are significantly higher than those of PD and PM, whereas, there is no such difference between the latter two preparations (Figure 2). The difference could be explained by corresponding difference in the dissolution profiles, that is, the higher the dissolution rate, the higher the drug serum concentration. Similar results have been reported by others (3,4,7,9) involving glibenclamide solid dispersions. The higher dissolution rate can also be accounted for the higher hypoglycemic effect of SD7 formulation (Figure 3).

In order to establish a reliable quantitative correlation between the in vivo and in vitro parameters of the drug, a Hill type equation was used in the form of the following double reciprocal linear relationships:

\[
\frac{1}{(AUC_b)_{0}^{tn}} = 0.0005 + 0.0152 \left[ \frac{1}{(AUC_d)_{0}^{tn}} \right]^{0.7366}
\]

\[r^2 = 0.9249, N = 18\]  

\[
\frac{1}{(AUC_{\Delta g})_{0}^{tn}} = 0.0256 + 0.3176 \left[ \frac{1}{(AUC_d)_{0}^{tn}} \right]^{0.6556}
\]

\[r^2 = 0.9717, N = 18\]  

\[
\frac{1}{(AUC_{\Delta g})_{0}^{tn}} = 0.0274 + 107.01 \left[ \frac{1}{(AUC_b)_{0}^{tn}} \right]^{1.4121}
\]

\[r^2 = 0.9784, N = 18\]  

where \((AUC_d)_{0}^{tn}, (AUC_b)_{0}^{tn}\) and \((AUC_{\Delta g})_{0}^{tn}\) are the areas under the drug dissolution, serum concentrations and
percent reduction of serum glucose concentrations relative to its zero time concentration vs. normalized time, tn, curves between zero and tn. The normalized time is the ratio of any in vivo and in vitro sampling time with respect to the corresponding last sampling time. The normalization of time is necessary to bring in vivo and in vitro times to the same scale. In the case of PD and PM the in vivo and in vitro normalized times can directly be found from the corresponding curves, however, for the SD formulation, the normalized in vitro times corresponding to in vivo normalized time are calculated via interpolation using the dissolution curve. N is the number of data and r² is coefficient of determination.

As it can be seen from equations 2-4, and the corresponding figures 6-8, there are excellent correlations between in vivo and in vitro parameters. These correlations indicate that both drug serum concentrations and its hypoglycemic effects are highly controlled by the drug dissolution. The higher the dissolution the higher is the corresponding in vivo parameter. The powers of the independent variables in the equations, which are obtained using iteration method, depend on kind of dependent variables used. The usefulness of such quantitative in vivo and in vitro correlations is self evident, because they could be used to predict in vivo parameters (such as areas under the drug serum concentration and hypoglycemic effect curves). In conclusion the solvent deposition technique can be employed as a reliable method for enhancing glibenclamide dissolution, serum concentrations and hypoglycemic effect. In addition, the quantitative correlations established between its in vivo and in vitro parameters can be fruitful as a simple approach for the predictive purposes.

REFERENCES


